BKC 005
Alternative Names: BKC-005; BR 1009Latest Information Update: 28 May 2022
At a glance
- Originator Boryung Pharmaceutical
- Class Antihypercalcaemics; Antihypertensives; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Hypertension
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Hypertension in South Korea (PO)
- 05 Apr 2018 Preclinical trials in Diabetes mellitus in South Korea (PO) (Boryung Pharmaceutical pipeline, April 2018)